What is US Stem Cell Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, US Stem Cell's Probability of Financial Distress (%) is 0.00%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of US Stem Cell's Probability of Financial Distress (%)
For the Biotechnology subindustry, US Stem Cell's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
US Stem Cell's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, US Stem Cell's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where US Stem Cell's Probability of Financial Distress (%) falls into.
US Stem Cell Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | 0.00 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 0.00% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
US Stem Cell (US Stem Cell) Business Description
Traded in Other Exchanges
N/A
Address
1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Executives
| Murphy William P Jr |
director |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
| Gregory Knutson |
director |
14855 ABERDEN STREET NE, HAM LAKE MN 55304 |
| Mark P Borman |
director |
5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410 |
| Charles A Hart |
director |
19345 RHINESTONE STREET NW, ANOKA MN 55303 |
| Sheldon T. Anderson |
director |
1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149 |
| Kristin C Comella |
officer: Chief Science Officer |
1310 LEEWARD WAY, WESTON FL 33327 |
| A Jones Lee |
director |
54 LOCKE LAKE RD, FRIDLEY MN 55432 |
| Karl Groth |
director |
1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029 |
| Matthew J Fendrich |
officer: Vice President,Sales&Marketing |
482 PEACOCK LANE SOUTH, JUPITER FL 33458 |
| Alan P Timmins |
director |
1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660 |
| Bruce C Carson |
director |
11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448 |
| Howard J Leonhardt |
director, 10 percent owner, officer: Executive Chairman & CTO |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
| Bromley R Scott |
officer: VP of Public Relations |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
| Richard Iii Spencer |
director |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
| Mike Tomas |
director |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
US Stem Cell (US Stem Cell) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
USRM has been successfully added to your